Answers are grounded in this paper and cite their sources.
BACKGROUND: Our aim was to determine if the historical principle of Lewis glycolipid neutralization of antibody and subsequent Lewis-incompatible transfusion could be extended and applied to the ABO blood group system using synthetic glycolipid-like constructs. STUDY DESIGN AND METHODS: In vitro experiments with human blood and blood group A function-spacer-lipid constructs (FSL-A) were used to determine rates and concentrations that caused antigen transformation and anti-A neutralization. FSL-A constructs were intravenously infused into naive and anti-A-immunized mice to determine in vivo antigen transformation, anti-A inhibition, and tolerance to A antigen-incompatible transfusions (A+biotin kodecytes). RESULTS: FSL-A was able to cause in vivo transformation of circulating mouse cells into A antigen-positive cells (in vivo A kodecytes) without consequence in animals either with or without circulating anti-A. FSL-A was able to neutralize circulating anti-A and allow for successful transfusion of incompatible A kodecytes. In the absence of FSL-A neutralization incompatible cells were rapidly destroyed. CONCLUSIONS: FSL constructs have the potential to neutralize circulating antibodies and allow for, or mitigate, the consequences of ABO-incompatible red blood cell transfusion.
No takes yet. Share an insight, caveat, or question.
Oliver et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: